NR2E3 and retinoblastoma: The drug repurposing screen in retinoblastoma Y79 cells, from which NR2E3 was first cloned [1], revealed that two proteasome inhibitors, Bortezomib and Carfilzomib, synergized with 11a to induce cell death at higher concentrations (Fig. 5G).